Description
SLU-PP-332 + BAM15 Combo is a research formulation with two complementary metabolic compounds: SLU-PP-332 as pan-agonist Estrogen-related Receptor (ERR) activator and BAM15 as mitochondrial proton channel uncoupler.
Per study reports the combo combines two independent metabolic mechanisms:
- SLU-PP-332 activates ERR-alpha, -beta and -gamma in skeletal muscle and adipose tissue and triggers an “exercise mimetic” gene expression program with increased oxidative capacity and fatty acid oxidation
- BAM15 uncouples the mitochondrial respiratory chain from ATP synthesis and forces the body to increased substrate oxidation as heat
Combined action in preclinical models is pronounced: marked fat loss without muscle mass loss, improved insulin sensitivity, increased basal metabolic rate. Both compounds are relatively new in preclinical research - human data is currently absent.
Both compounds are orally available and come together in one capsule here.
You can order SLU-PP-332 + BAM15 Combo as capsules in one bottle with 60 pieces, each capsule with 250mcg SLU-PP-332 and either 50mcg or 50mg BAM15.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
This combo joins two young metabolic compounds, an ERR agonist and a mitochondrial uncoupler. Both have only been in preclinical research for a few years; human data is entirely absent.
Documented in the preclinical literature:
- Mitochondrial uncoupler: BAM15 uncouples the respiratory chain from ATP synthesis and forces the body to increased substrate oxidation as heat. Mitochondrial uncouplers are a mechanistically interventional compound class. The dose window is described in the literature as relevant.
- Broad metabolic intervention: the ERR component additionally activates several nuclear receptor programs. The combination thus addresses two independent metabolic axes simultaneously.
- No human data: no clinical studies exist for either individual compound, let alone for the combo. Statements on tolerability and dosing in humans cannot be derived from the literature.
- Young data: all the evidence comes from a few preclinical studies; independent replication is largely outstanding.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity - ACS Chemical Biology 2023, Billon et al: original characterization of SLU-PP-332 as pan-ERR agonist and exercise mimetic.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome - Journal of Pharmacology and Experimental Therapeutics 2024, Billon et al: SLU-PP-332 in a metabolic syndrome mouse model.
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function - Circulation 2024, Xu et al: SLU-PP-332 class in a heart failure model.
- Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice - Nature Communications 2020, Alexopoulos et al: BAM15 obesity and insulin resistance study.
- BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control - EMBO Molecular Medicine 2020, Axelrod et al: BAM15 mechanism study on mitochondrial uncoupling and glycemic control.
